---
title: "Imeik Technology Development Co.,Ltd (300896.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300896.SZ.md"
symbol: "300896.SZ"
name: "Imeik Technology Development Co.,Ltd"
industry: "Biotechnology"
datetime: "2026-05-19T23:12:44.087Z"
locales:
  - [en](https://longbridge.com/en/quote/300896.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300896.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300896.SZ.md)
---

# Imeik Technology Development Co.,Ltd (300896.SZ)

## Company Overview

Imeik Technology Development Co.,Ltd. engages in the research and development, and transformation of biomedical materials and biopharmaceutical products in China. The company offers aesthetic medicine products, such as cross-linked sodium hyaluronate gel with PLLA-b-PEG microsphere; poly facial implant thread; medical sodium hyaluronate-hydroxypropyl methylcellulose gel; sodium hyaluronate composite solution for injection; modified sodium hyaluronate gel for injection; medical PVA gel ball-sodium hyaluronate-hydroxypropyl methylcellulose gel; and skin care products. It serves medical aesthetic institutions.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.imeik.net/cn](https://www.imeik.net/cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: C (0.46)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 22 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -15.90% |  |
| Net Profit YoY | -38.87% |  |
| P/B Ratio | 4.16 |  |
| Dividend Ratio | 1.84% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 32709196695.38 |  |
| Revenue | 2420595196.87 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 14.22% | B |
| Profit Margin | 47.28% | A |
| Gross Margin | 92.49% | A |
| Revenue YoY | -15.90% | E |
| Net Profit YoY | -38.87% | D |
| Total Assets YoY | 4.80% | C |
| Net Assets YoY | 0.74% | C |
| Cash Flow Margin | 108.54% | C |
| OCF YoY | -15.90% | E |
| Turnover | 0.27 | D |
| Gearing Ratio | 7.43% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Imeik Technology Development Co.,Ltd",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-15.90%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-38.87%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.16",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.84%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "32709196695.38",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2420595196.87",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "14.22%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "47.28%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "92.49%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-15.90%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-38.87%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "4.80%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "0.74%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "108.54%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-15.90%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.27",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "7.43%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 28.37 | 9/81 | 32.50 | 29.99 | 28.29 |
| PB | 4.13 | 52/81 | 6.84 | 6.23 | 5.72 |
| PS (TTM) | 13.41 | 58/81 | 19.57 | 18.01 | 16.81 |
| Dividend Yield | 1.85% | 14/81 | 3.52% | 3.11% | 2.06% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T16:00:00.000Z

Total Analysts: **14**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 64% |
| Overweight | 1 | 7% |
| Hold | 3 | 21% |
| Sell | 1 | 7% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 107.41 |
| Highest Target | 188.00 |
| Lowest Target | 110.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300896.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300896.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300896.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300896.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**